ETON Valuation

Eton Pharmaceuticals Inc

Add to Watchlist

Advanced Chart

15.400

+0.03(0.195%)1D

Overview
Forecast
Valuation
Earnings

ETON Relative Valuation

ETON's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ETON is overvalued; if below, it's undervalued.

Historical Valuation

Eton Pharmaceuticals Inc (ETON) is now in the Fair zone, suggesting that its current forward PS ratio of 4.89 is considered Fairly compared with the five-year average of 21.58. The fair price of Eton Pharmaceuticals Inc (ETON) is between 5.86 to 18.96 according to relative valuation methord.

Relative Value

Fair Zone

5.86-18.96

Current Price：15.40

Fair

Trailing

Forward

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

16.89

P/B

Median3y

9.85

Median5y

15.09

1.34

FCF Yield

Median3y

2.37

Median5y

-1.85

Competitors Valuation Multiple

The average P/S ratio for ETON's competitors is 2.52, providing a benchmark for relative valuation. Eton Pharmaceuticals Inc Corp (ETON) exhibits a P/S ratio of 4.89, which is 93.72% above the industry average. Given its robust revenue growth of 116.95%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

ETON.O

Eton Pharmaceuticals Inc

4.89

Average P/S: 2.52

116.95%